Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Gamma-ketoaldehyde scavengers for alcoholic liver disease

Award Number: R43AA023715
ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/25/2014
PERIOD OF PERFORMANCE END DATE: 02/28/2015

Group Awards By:

View Award Description

Gamma-ketoaldehyde scavengers for alcoholic liver disease - DESCRIPTION (provided by applicant): Chronic alcohol overconsumption is the third largest risk factor for disease burden worldwide and is a frequent comorbidity of liver disease and cancer. While abstinence is a cornerstone of treatment, there is considerable interest in identifying other therapeutic interventions for alcoholic liver disease (ALD). Such advances are complicated by an incomplete understanding of the relationship between alcohol-specific metabolic responses and liver pathophysiology. The induction of a pro-inflammatory state, hallmark of ALD, appears to depend upon the unfavorable interplay among reactive oxygen species (ROS), protein adduct formation, and both the innate and adaptive immune responses. In this SBIR Phase I project, we hypothesize that the formation of highly reactive compounds, termed ¿-ketoaldehydes (¿-KA), formed primarily by non-enzymatic free radical catalyzed lipid peroxidation and secondarily by cyclooxygenases (COX) activity, is crucial for ethanol-induced liver injury. ¿-KAs react very rapidly with protein lysyl residues to form stable lactam adducts which elicit specific immune reactions. The formation of these ¿-KA-protein adducts lead to immunogenicity, inflammation and end-organ damage. Hence, the use of selective scavengers of ¿-KAs should lead to interruption of the pathogenic inflammatory responses leading to improvements in ALD. It has become increasingly evident that the interplay among ROS, lipid peroxidation and immune responses is important in the pathogenesis of ALD. Our collaborator (LJ Roberts, MD) has identified Salicylamine as an agent that rapidly and preferentially reacts with ¿-KAs to prevent their adduction to cellular proteins and other amines. The goal of this proposal is to test the hypothesis that hepatic ¿-KA scavenging will reduce liver injury (ALT) and have differential effects on innate and adaptive immune responses in ALD. We will determine the effects of orally administered Salicylamine on reducing the severity of alcohol liver injury an on immune responses in acute (2 day) and chronic (25 day) ethanol-fed mouse models. In study 1, we will examine the dose-response effects of Salicylamine on liver function (ALT, AST, triglyceride), as well as hepatic and circulating ¿-KAs, anti-¿-KA antibody titers as well as livr monocyte infiltration when Salicylamine is administered concurrent with ethanol. We anticipate Salicylamine will significantly reduce protein adduction formation and improve liver function in a manner that is concordant with diminished adaptive immune responses including T and B cell proliferation, NF¿B activation and TLR4 signaling. In study 2 we will employ the same 2 day and 25 day ethanol-fed mouse models to induce liver injury, but will administer Salicylamine (in a dose-dependent manner) after the primary ethanol administration then monitor the same endpoints as in study 1. If these studies demonstrate that Salicylamine reduces alcohol liver injury and/or have a differential effect on immune responses, Phase II studies will be proposed to further refine the mechanisms of action of Salicylamine desired for product development and regulatory approvals in a subsequent SBIR grant.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2014 ( Subtotal = $151,587 )
2014	2014	METABOLIC TECHNOLOGIES, INC	2625 NORTH LOOP DR, STE 2150	AMES	IA	50010	STORY	USA	Alcohol Research Programs	000	1	9/24/2014	NEW	$151,587
														Subtotal = $151,587

Grand Total All Awards = $151,587

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Gamma-ketoaldehyde scavengers for alcoholic liver disease

Award Number: R43AA023715

ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/25/2014

PERIOD OF PERFORMANCE END DATE: 02/28/2015

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer